– USA, WA – Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Kelly Romano to its Board of Directors.
Ms. Romano is the Founder and Chief Executive Officer of BlueRipple Capital, LLC, a consultancy firm for global technology companies.
“As we expanded our Board, we sought a candidate who would help us best serve shareholders as we work towards making new treatments available for patients through the continued advancement of our Phase 2/3 clinical studies for ATH-1017 in Alzheimer’s disease,” said CEO, Dr. Leen Kawas. “Kelly has a track record of operational success and an aptitude for understanding growing companies as we continue to drive the business forward.”
About Kelly Romano
Ms. Romano brings over 30 years of executive operating experience in technology, with a background in commercial buildings and aerospace. In addition to her role at BlueRipple Capital, LLC, Ms. Romano is an Operating Partner at AE Industrial Partners. Previously, she spent 32 years working at United Technologies Corp. in various positions of increasing responsibility, most recently as President of Intelligent Building Technologies in UTC Building & Industrial Systems.
Ms. Romano is also a member of several boards of directors, including UGI Corporation and Dorman Products, Inc., and is co-chair of the board of directors at Potter Electric Signal.
Ms. Romano commented, “I am honored to be joining Athira’s Board to leverage my experience with business and technology as the company recruits for its ongoing clinical trials of ATH-1017. I strongly support Athira’s critical mission to develop therapies that have the potential to benefit patients with neurodegenerative disease, space where treatment options are limited.”
Ms. Romano holds a bachelor’s degree in business administration from the State University of New York at Buffalo, an MBA degree from Syracuse University, and is a graduate of the Northwestern University Kellogg School of Management’s Corporate Board Governance Executive Program, as well as senior executive programs at Darden School of Management, University of Virginia.
About Athira Pharma, Inc.
Athira, headquartered in Seattle, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. We aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimer’s disease and Parkinson’s disease dementia.
For more information: https://www.athira.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.